Ashland Inc
F:AHT

Watchlist Manager
Ashland Inc Logo
Ashland Inc
F:AHT
Watchlist
Price: 52 EUR 2.97% Market Closed
Market Cap: 2.7B EUR

Ashland Inc
Investor Relations

Ashland Inc. has transformed remarkably since its origins as a regional oil refiner at the turn of the 20th century. Today, it stands as a global specialty chemicals company, with a rich tapestry of innovation in delivering products that bind, coat, and improve materials. The heart of Ashland’s operations beats strongest in its specialty ingredients and performance materials, which find their way into diverse industries such as personal care, pharmaceuticals, and food and beverage. By leveraging its expertise in chemistry and its relentless pursuit of quality, the company crafts solutions like polymers and adhesives which enhance the performance and efficacy of everyday products, creating substantial demand in the market.

At the core of Ashland’s profit engine is its ability to anticipate and adapt to the intricate needs of its industrial clientele. The company generates revenue by developing customized chemical solutions that help improve the product performance of its clients, whether it's producing more vibrant paints or ensuring the consistency of pharmaceutical tablets. Ashland’s business model capitalizes on both its innovative prowess and its strategic relationships across the global supply chain, positioning itself not merely as a supplier, but as a strategic partner capable of delivering added value through innovation. This client-centric approach ensures a steady flow of contracts and repeat business, anchoring its position as a pivotal player in the specialty chemicals domain.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2025
Call Date
Nov 5, 2025
AI Summary
Q4 2025

Sales & Earnings: Ashland reported Q4 sales of $478 million, down 8% year-over-year, but in line with guidance. Adjusted EBITDA was $119 million, a 4% decrease, also matching expectations.

Margins: Adjusted EBITDA margin expanded to 24.9%, up 110 basis points, hitting the company’s long-term target of 25%. Life Sciences and Personal Care both delivered margins at or above 30%.

Portfolio Actions: Declines in reported sales and EBITDA were primarily due to portfolio optimization; excluding these, sales and EBITDA both grew year-over-year.

2026 Guidance: Ashland projects fiscal 2026 sales of $1.835–$1.905 billion (1% to 5% organic growth), adjusted EBITDA of $400–$430 million, and expects double-digit adjusted EPS growth.

Cost & Cash: Manufacturing optimization and restructuring are ahead, with $50–$55 million in savings targeted for 2026. Free cash flow was $52 million in Q4 and is targeted at 50% EBITDA conversion for 2026.

Business Unit Trends: Life Sciences and Personal Care show resilience and growth, while Specialty Additives faces regional headwinds, especially in China. Intermediates remain pressured by low pricing and volumes.

Key Financials
Sales
$478 million
Adjusted EBITDA
$119 million
Adjusted EBITDA Margin
24.9%
Adjusted EPS
$1.08
Free Cash Flow
$52 million
Life Sciences Sales
$173 million
Life Sciences Adjusted EBITDA
$55 million
Personal Care Sales
$151 million
Personal Care Adjusted EBITDA
$43 million
Specialty Additives Sales
$131 million
Specialty Additives Adjusted EBITDA
$29 million
Intermediates Sales
$33 million
Intermediates Adjusted EBITDA
$5 million
Total Liquidity
just over $800 million
Net Leverage
2.9x (mid-2s after tax refund)
Capital Expenditures
$100 million (FY 2026 target)
Earnings Call Recording
Other Earnings Calls

Management

Mr. Guillermo Novo
Chairman & CEO
No Bio Available
Mr. John Kevin Willis
Senior VP & CFO
No Bio Available
Dr. Osama M. Musa Ph.D.
Senior VP & CTO
No Bio Available
Mr. Karl R. Bostaph
Senior Vice President of Operations
No Bio Available
Mr. Eric N. Boni
VP of Finance & Principal Accounting Officer
No Bio Available
Mr. William C. Whitaker C.F.A.
Director of Investor Relations
No Bio Available
Ms. Robin E. Lampkin
Senior VP, General Counsel & Secretary
No Bio Available
Ms. Eileen M. Drury
Senior VP & Chief HR Officer
No Bio Available
Mr. James Minicucci
Senior VP & GM of Personal Care
No Bio Available
Ms. Alessandra Faccin Assis
Senior VP and GM of Life Sciences & Intermediates
No Bio Available

Contacts

Address
DELAWARE
Wilmington
8145 Blazer Drive
Contacts
+13049953000
www.ashland.com